Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adult Solid Neoplasm × Erlotinib Hydrochloride × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Papillary renal cell carcinoma, sporadic 1 Pancreatic Intraductal Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Hereditary leiomyomatosis and renal cell cancer 1 Carcinoma, Renal Cell 1 Adult Solid Neoplasm 1

Interventions

temsirolimus 1 ixabepilone 1 Sirolimus 1 Irinotecan 1 Erlotinib Hydrochloride 1 Epothilones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00045201 2026-03-18

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡